摘要
目的评价脐血单个核细胞经静脉途径治疗心力衰竭的安全性和有效性。方法选择慢性终末期心力衰竭患者21例,心功能分级(NYHA)Ⅳ级。行脐血单个核细胞经静脉途径治疗,观察治疗前、治疗后1、3及6个月心功能、血浆N末端钠尿肽前体(NT-proBNP)、LVEF、左心室舒张末期内径(LVEDD)等指标。结果 21例心力衰竭患者中,20例有效,1例无效,30d内死亡。心力衰竭患者治疗后1、3个月心功能Ⅱ、Ⅲ级比例较治疗前明显升高(90.5%,95.2%vs 0%,P<0.05),NT-proBNP水平较治疗前明显降低[(3045.3±103.8)ng/L,(3367.5±111.4)ng/L vs(5312.1±121.9)ng/L,P<0.05)]。结论脐血单个核细胞经静脉途径治疗终末期心力衰竭安全性高,无明显副作用,在一定时期内可改善心功能、缓解心力衰竭症状及提高患者生活质量。
Objective To assess the safety and efficacy of intravenous umbilical cord blood mononuclear cells in treatment of end stage heart failure（HF）.Methods Twenty-one end stage HF patients with cardiac functionⅣaccording to NYHA were treated with intravenous umbilical cord blood mononuclear cells.Their cardiac function was assessed,their NT-proBNP,LVEF,LVEDD were measured before and after treatment for 1 month,3 months and 6 months.Results Umbilical cord blood mononuclear cells were effective for 20 patients and ineffective for 1 patient who died within 30 days after treatment.The rate of improved cardiac function Ⅱ and Ⅲ was significantly higher while the serum NT-proBNP level was significantly lower after treatment for 1 month and 3 months（90.5%,95.2%vs 0%,P〈0.05;3045.3±103.8 ng/L,3367.5±111.4 ng/Lvs5312.1±121.9 ng/L,P〈0.05）.Conclusion Intravenous umbilical cord blood mononuclear cells are safe for end stage HF patients,alleviate their symptoms,improve their cardiac function and quality of life with no significant side effect.
作者
高东学
刘艳华
王磌
Gao Dongxue;Liu Yanhua;Wang Tian(Department of Cardiology, Shandong Provincial Third Hospital, J innan 250031, Shandong Province, China)
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2018年第4期382-384,共3页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词
胎血
单核细胞
心力衰竭
干细胞移植
fetal blood
monocytes
heart failure
stem cell transplantation
